<DOC>
	<DOC>NCT01000896</DOC>
	<brief_summary>The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.</brief_summary>
	<brief_title>Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Japanese patients with non small cell lung cancer or epithelial ovarian cancer Must be suitable for treatment with carboplatin and paclitaxel Relatively good overall health other than cancer Poor bone marrow function (not producing enough blood cells). Poor liver or kidney function. Patients unable to discontinue drugs known to be potent inhibitors or inducers of CYP3A4 within 2 weeks prior to registration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>cancer</keyword>
	<keyword>solid tumors</keyword>
	<keyword>advanced solid malignancies</keyword>
	<keyword>NSCLC</keyword>
	<keyword>epithelial ovarian cancer</keyword>
	<keyword>dose escalation</keyword>
	<keyword>combination treatment</keyword>
	<keyword>src inhibitor</keyword>
	<keyword>Japanese</keyword>
</DOC>